Remission of refractory hepatitis C-negative cryoglobulinaemic vasculitis after rituximab and infliximab.
Koukoulaki
Maria
M
The Vasculitis and SLE Unit, Department of Medicine, University of Cambridge School of Clinical Medicine, UK.
Abeygunasekara
Sumith C
SC
Smith
Kenneth G C
KG
Jayne
David R W
DR
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D003449:Cryoglobulinemia / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D016174:Hepacivirus; D006526:Hepatitis C; D006801:Humans; D000069285:Infliximab; D008875:Middle Aged; D018570:Risk Assessment; D000069283:Rituximab; D016896:Treatment Outcome; D014657:Vasculitis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D000069285:Infliximab